FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?

Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet